human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) Report issue

Vaccine Approved FDA
AACT

Active Ingredient History

NOW
  • Now
Gardasil is an HPV vaccine for use in the prevention of certain strains of human papillomavirus (HPV). It was developed by Merck & Co. High-risk human papilloma virus (hr-HPV) genital infection is the most common sexually transmitted infection among women. The HPV strains that Gardasil protects against are sexually transmitted, specifically HPV types 6, 11, 16 and 18. HPV types 16 and 18 cause an estimated 70% of cervical cancers, and are responsible for most HPV-induced anal, vulvar, vaginal, and penile cancer cases. HPV types 6 and 11 cause an estimated 90% of genital warts cases. HPV type 16 is responsible for almost 90% of HPV-positive oropharyngeal cancers, and the prevalence is higher in males than females. Though Gardasil does not treat existing infection, vaccination is still recommended for HPV-positive individuals, as it may protect against one or more different strains of the disease.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

9-valent hpv vaccine | gardasil 9 | human papillomavirus 9-valent vaccine, recombinant | human papillomavirus vaccine | human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) | nonavalent hpv vaccine | recombinant human papillomavirus nonavalent vaccine | v503

Organizations (81)

Research & Development (81)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (38)

Approved Indications (1)


 

Papillomavirus Vaccines (approved 2014)

Experimental Indications - Clinical Trial Phases 1-4 (38)


 

Acquired Immunodeficiency Syndrome (Phase 3)

Adenocarcinoma in Situ (Phase 3)

Alphapapillomavirus (Phase 3)

Androgens (Phase 3)

Anus Neoplasms (Phase 3)

Carcinoma (Phase 4)

Carcinoma, Squamous Cell (Phase 3)

Cervical Intraepithelial Neoplasia (Phase 4)

Condylomata Acuminata (Phase 3)

COVID-19 (Phase 3)

Dengue (Phase 3)

Drug Evaluation (Phase 4)

Drugs, Investigational (Phase 2)

Genital Diseases (Phase 3)

Head and Neck Neoplasms (Phase 1/Phase 2)

Healthy Volunteers (Phase 3)

Hematopoietic Stem Cell Transplantation (Phase 4)

HIV (Phase 4)

HIV Infections (Phase 4)

Human papillomavirus 16 (Phase 4)

Immunization (Phase 4)

Inflammatory Bowel Diseases (Phase 4)

Lung Diseases (Early Phase 1)

Lymphoma (Phase 4)

Neoplasms (Phase 4)

Papilloma (Phase 3)

Papillomaviridae (Phase 4)

Papillomavirus Infections (Phase 4)

Papillomavirus Vaccines (Phase 4)

Penile Neoplasms (Phase 1/Phase 2)

Pharmacological and Toxicological Phenomena (Phase 3)

Thrombocytopenia (Phase 2)

Transplants (Phase 3)

Uterine Cervical Dysplasia (Phase 4)

Uterine Cervical Neoplasms (Phase 4)

Vaginal Neoplasms (Phase 3)

Vulvar Neoplasms (Phase 4)

Warts (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 96
  • # of Trial Organizations: 81

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue